Intercept Pharmaceuticals

Intercept Pharmaceuticals is a biopharmaceutical company headquartered in New Jersey. As a wholly owned subsidiary of Alfasigma S.p.A., Intercept focuses on developing and commercializing innovative treatments for rare and serious liver diseases. With approximately 437 employees, the company generated $370.4 million in revenue. Intercept specializes in therapies for conditions such as primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). Their mission is to provide vital treatments that address the needs of patients living with these challenging liver diseases. The company is dedicated to improving patients’ lives and making a significant impact on the liver disease community. Intercept Pharmaceuticals distinguishes itself through its commitment to developing novel therapeutics that target specific needs within the liver disease landscape. The company's focus on rare and serious conditions underscores its dedication to serving patients facing complex medical challenges. For more information about Intercept Pharmaceuticals and its work, please visit www.interceptpharma.com. You can also follow the company on X at @InterceptPharma.